People · Operator
Named in public records as an officer, director or promoter · active 2026–2026 · Biotechnology, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Nasus Pharma Ltd | — | Biotechnology | Series B | $15.0M | $53.6M | 2026 |
| PingPod Inc | — | Other Technology | Seed | $1.1M | $2.6M | 2026 |
David Silberman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Silberman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Sharon Shacham | 1 | 4 |
| Dalia Megiddo | 1 | 3 |
| Isaac Israel | 1 | 2 |
| Dan Teleman | 1 | 2 |
| Udi Gilboa | 1 | 2 |
| Ronnie Hershman | 1 | 2 |
| Eyal Rubin | 1 | 1 |
| Tate Searle | 1 | 1 |
| Kim Lapus | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.